Genmab to File sBLA for Epcoritamab with FDA
Ticker: GNMSF · Form: 6-K · Filed: May 2, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | May 2, 2025 |
| Risk Level | low |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-filing, sBLA, oncology, FDA
TL;DR
Genmab filing new FDA application for epcoritamab based on positive trial data.
AI Summary
Genmab A/S announced on May 2, 2025, that it will submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for its drug epcoritamab. This submission is based on positive results from the EPCORE DLBCL Part 2 study, which evaluated epcoritamab as a monotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Why It Matters
This regulatory submission could expand the approved uses of epcoritamab, potentially increasing its market reach and revenue for Genmab.
Risk Assessment
Risk Level: low — This is a routine regulatory filing based on positive clinical trial data, not indicating any immediate negative financial or operational risks.
Key Players & Entities
- Genmab A/S (company) — Registrant and filer of the 6-K
- epcoritamab (drug) — Drug for which an sBLA is being submitted
- U.S. Food and Drug Administration (FDA) (company) — Regulatory body receiving the sBLA
- EPCORE DLBCL Part 2 study (study) — Clinical trial providing data for the sBLA
- May 2, 2025 (date) — Date of the company announcement
FAQ
What is the purpose of the Supplemental Biologics License Application (sBLA) being submitted by Genmab?
The sBLA is being submitted to the U.S. Food and Drug Administration (FDA) to seek approval for epcoritamab as a monotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
What study results support this sBLA submission?
The submission is based on positive results from the EPCORE DLBCL Part 2 study.
What is the specific indication Genmab is seeking for epcoritamab with this sBLA?
Genmab is seeking approval for epcoritamab as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients who have undergone two or more prior lines of systemic therapy.
When did Genmab announce this filing intention?
Genmab announced its intention to submit the sBLA on May 2, 2025.
Is this a new drug application or a supplemental one?
This is a Supplemental Biologics License Application (sBLA), indicating it is for an expansion of an existing drug's approved use or indication.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 2, 2025 regarding GENMAB A/S (GNMSF).